HRP20202073T1 - Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori - Google Patents
Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori Download PDFInfo
- Publication number
- HRP20202073T1 HRP20202073T1 HRP20202073TT HRP20202073T HRP20202073T1 HR P20202073 T1 HRP20202073 T1 HR P20202073T1 HR P20202073T T HRP20202073T T HR P20202073TT HR P20202073 T HRP20202073 T HR P20202073T HR P20202073 T1 HRP20202073 T1 HR P20202073T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- cancer
- solvate
- image
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- ZBGWAJQUDSCDPB-UHFFFAOYSA-N n-(benzenesulfonyl)benzamide Chemical class C=1C=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1 ZBGWAJQUDSCDPB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000004253 NUT midline carcinoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Claims (10)
1. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, pri čemu je spoj odabran iz grupe koja se sastoji od:
[image]
2. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol ili solvat, koji je:
[image]
3. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol ili solvat, koji je:
[image]
4. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol ili solvat, koji je:
[image]
5. Farmaceutska kompozicija koja sadrži spoj iz patentnog zahtjeva 1, ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač.
6. Farmaceutska kompozicija iz patentnog zahtjeva 5, pri čemu je spoj:
[image]
7. Farmaceutska kompozicija iz patentnog zahtjeva 5, pri čemu je spoj:
[image]
8. Farmaceutska kompozicija iz patentnog zahtjeva 5, pri čemu je spoj:
[image]
9. Spoj iz bilo kog patentnog zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol ili solvat, ili farmaceutska kompozicija iz bilo kojeg patentnog zahtjeva 5 do 8, za primjenu u liječenju ili prevenciji bolesti, poremećaja ili stanja kod subjekta.
10. Spoj iz bilo kojeg patentnog zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol ili solvat, ili farmaceutska kompozicija iz bilo kojeg patentnog zahtjeva 5 do 8, za primjenu u liječenju raka kod subjekta, pri čemu je rak odabran iz grupe koja se sastoji od akutne monocitne leukemije, akutne mijelogene leukemije, kronične mijelogene leukemije, kronične limfocitne leukemije leukemije mješovitih linija, NUT srednjelinijskog karcinoma, multiplog mijeloma, sitnostaničnog raka pluća, neuroblastoma, Burkittovog limfoma, raka grlića materice, ezofagealnog raka, raka jajnika, kolorektalnog raka, raka prostate, i raka dojke.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662371504P | 2016-08-05 | 2016-08-05 | |
US201762454101P | 2017-02-03 | 2017-02-03 | |
PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
EP17754889.8A EP3494115B1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20202073T1 true HRP20202073T1 (hr) | 2021-02-19 |
Family
ID=59677319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20202073TT HRP20202073T1 (hr) | 2016-08-05 | 2020-12-29 | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori |
Country Status (26)
Country | Link |
---|---|
US (3) | US10829488B2 (hr) |
EP (3) | EP4129999A1 (hr) |
JP (2) | JP6651180B2 (hr) |
KR (2) | KR102429704B1 (hr) |
CN (2) | CN110483501B (hr) |
AU (2) | AU2017305508B2 (hr) |
BR (1) | BR112019001666A2 (hr) |
CA (1) | CA3031419C (hr) |
CY (1) | CY1123859T1 (hr) |
DK (1) | DK3494115T3 (hr) |
ES (1) | ES2849959T3 (hr) |
HR (1) | HRP20202073T1 (hr) |
HU (1) | HUE053414T2 (hr) |
IL (2) | IL264059B (hr) |
LT (1) | LT3494115T (hr) |
MX (2) | MX2019001391A (hr) |
PE (1) | PE20190711A1 (hr) |
PH (1) | PH12019500231A1 (hr) |
PT (1) | PT3494115T (hr) |
RS (1) | RS61821B1 (hr) |
RU (3) | RU2744358C2 (hr) |
SA (1) | SA519401020B1 (hr) |
SG (2) | SG11201900135YA (hr) |
SI (1) | SI3494115T1 (hr) |
WO (1) | WO2018027097A1 (hr) |
ZA (2) | ZA201900240B (hr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3426655A1 (en) * | 2016-03-10 | 2019-01-16 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
EP4129999A1 (en) * | 2016-08-05 | 2023-02-08 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
PT3612531T (pt) * | 2017-04-18 | 2022-10-04 | Shanghai Fochon Pharmaceutical Co Ltd | Agentes indutores de apoptose |
EP3788042A4 (en) | 2018-04-29 | 2022-01-26 | BeiGene, Ltd. | BCL-2 INHIBITORS |
UA125241C2 (uk) | 2018-07-31 | 2022-02-02 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP |
KR20210003731A (ko) | 2018-07-31 | 2021-01-12 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도 |
CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
WO2020103921A1 (en) * | 2018-11-23 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and use thereof |
TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
CN112294966B (zh) * | 2019-07-31 | 2021-12-17 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
US20220317127A1 (en) * | 2019-11-27 | 2022-10-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
TWI772992B (zh) * | 2019-12-03 | 2022-08-01 | 大陸商蘇州亞盛藥業有限公司 | 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物 |
EP4069233A4 (en) * | 2019-12-04 | 2024-03-13 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND USE THEREOF |
JP7142173B2 (ja) | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー, インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
WO2021175321A1 (en) * | 2020-03-06 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates |
US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
CN113880834B (zh) * | 2020-07-01 | 2023-01-20 | 苏州亚盛药业有限公司 | N-(苯基磺酰基)苯甲酰胺类化合物及其中间体的合成方法 |
CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
BR112023000320A2 (pt) * | 2020-07-10 | 2023-01-31 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso |
CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ(スーチョウ)カンパニー,リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
US20240016747A1 (en) * | 2020-11-25 | 2024-01-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
WO2022143602A1 (en) * | 2020-12-28 | 2022-07-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
CN114835704B (zh) * | 2021-02-01 | 2023-10-27 | 苏州亚盛药业有限公司 | 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物 |
WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
WO2023011488A1 (zh) | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
JP2010511407A (ja) | 2006-12-04 | 2010-04-15 | アボット・ラボラトリーズ | 癌治療のためのコンパニオン診断アッセイ |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
MX2011005922A (es) | 2008-12-05 | 2011-06-16 | Abbott Lab | Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes. |
CN104945311A (zh) | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
WO2010093742A1 (en) | 2009-02-11 | 2010-08-19 | Abbott Laboratories | Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI537269B (zh) | 2009-05-26 | 2016-06-11 | 艾伯維巴哈馬有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑 |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
WO2012071374A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
US10362975B2 (en) | 2015-12-30 | 2019-07-30 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors |
EP4129999A1 (en) * | 2016-08-05 | 2023-02-08 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
-
2017
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active IP Right Grant
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 BR BR112019001666A patent/BR112019001666A2/pt active Search and Examination
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active IP Right Grant
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 MX MX2019001391A patent/MX2019001391A/es unknown
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
- 2020-10-23 RU RU2020134802A patent/RU2020134802A/ru unknown
- 2020-12-29 HR HRP20202073TT patent/HRP20202073T1/hr unknown
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
HRP20171151T1 (hr) | Inhibitori cdc7 | |
HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
HRP20210319T1 (hr) | Kombinacije inhibitora fgfr i inhibitora igf1r | |
HRP20220258T1 (hr) | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora | |
MD3313850T2 (ro) | Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin | |
PH12017502246A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
HRP20131081T1 (hr) | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera | |
GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
BR112013004368A2 (pt) | compostos tendo a fórmula geral (i) e composição farmacêutica | |
CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
HRP20210537T1 (hr) | Upotreba inhibitora faktora induciranog hipoksijom | |
PH12018500377A1 (en) | Novel annelated benzamides | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 |